Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.57 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.52 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1591865 | 1.00 | KDM4E (0.65) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL4510409 | 1.00 | KDM4E (0.65) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL1591329 | 1.00 | KDM4E (0.65) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL2305974 | 0.87 | KDM4E (0.51) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL31024625 | 0.87 | KDM4E (0.51) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL25111516 | 0.84 | KDM4E (0.49) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL12703742 | 0.84 | KDM4E (0.49) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL17128008 | 0.84 | KDM4E (0.49) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL1592053 | 0.84 | KDM4E (0.49) | KDM4EHTTCYP2A13FUCA1ACHE | |
| SCHEMBL17128035 | 0.84 | KDM4E (0.49) | KDM4EHTTCYP2A13FUCA1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108101860-B | Preparation method of cis-2, 6-dimethyl morpholine | 苏州敬业医药化工有限公司 | 2021-11-23 | — | — | CN | claimed |
| CN-108101860-B | Preparation method of cis-2, 6-dimethyl morpholine | 苏州敬业医药化工有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-108101860-B | Preparation method of cis-2, 6-dimethyl morpholine | 苏州敬业医药化工有限公司 | 2021-11-23 | — | — | CN | disclosed |
| EP-1961750-B1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO CO LTD (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-8420646-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PAH P&U LLC (US) | 2013-04-16 | — | — | US | disclosed |
| US-20130065882-A1 | VLA-4 inhibitory drug | MACHINAGA NOBUO (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-21 | — | — | US | disclosed |
| US-8129366-B2 | VLA-4 inhibitory drug | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | PHARMACIA & UPJOHN COMPANY | 2011-04-21 | — | — | US | disclosed |
| EP-1551849-B1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2010-07-14 | — | — | EP | disclosed |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | PHARMACIA & UPJOHN COMPANY | 2010-01-28 | — | — | US | disclosed |
| US-7605157-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961750-A1 | VLA-4 INHIBITORY DRUG | Daiichi Sankyo Company, Limited (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1888597-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2007-07-12 | — | — | US | disclosed |
| US-7208490-B2 | Tricyclic tetrahydroquinoline antibacterial agents | PHARMACIA & UPJOHN COMPANY LLC (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2006120563-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-16 | — | — | WO | disclosed |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | ZOETIS SERVICES LLC | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092494-A1 | Tricyclic Tetrahydroquinoline Antibacterial Agents | QTRT1, QTRT2, NQO2 | KDM4E 1604/4885HTT 1097/4885CYP2A13 3159/4885 |
| US-20120157437-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | KDM4E 983/4885HTT 4675/4885CYP2A13 514/4885 |
| US-20130065882-A1 | VLA-4 inhibitory drug | VCAM1, ITGB4, ITGA4 | KDM4E 996/4885HTT 4730/4885CYP2A13 559/4885 |
| US-20070161630-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | KDM4E 1604/4885HTT 1097/4885CYP2A13 3159/4885 |
| US-20040162279-A1 | Tricyclic tetrahydroquinoline antibacterial agents | QTRT1, QTRT2, NQO2 | KDM4E 1604/4885HTT 1097/4885CYP2A13 3159/4885 |
| US-20090233901-A1 | VLA-4 INHIBITORY DRUG | VCAM1, ITGB4, ITGA4 | KDM4E 1607/4885HTT 4814/4885CYP2A13 783/4885 |
| US-20100022524-A1 | TRICYCLIC TETRAHYDROQUINOLINE ANTIBACTERIAL AGENTS | QTRT1, QTRT2, NQO2 | KDM4E 1604/4885HTT 1097/4885CYP2A13 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.